Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,008 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subsequent Upper Urinary Tract Carcinoma Related to Worse Survival in Patients Treated with BCG.
Numakura K, Miyake M, Kobayashi M, Muto Y, Sekine Y, Nishimura N, Iida K, Shiga M, Morizane S, Yoneyama T, Matsumura Y, Abe T, Yamada T, Matsumoto K, Inokuchi J, Nishiyama N, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K, Habuchi T. Numakura K, et al. Among authors: muto y. Cancers (Basel). 2023 Mar 28;15(7):2002. doi: 10.3390/cancers15072002. Cancers (Basel). 2023. PMID: 37046663 Free PMC article.
Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes.
Numakura K, Kobayashi M, Hatakeyama S, Naito S, Horikawa Y, Tanaka T, Kamada S, Muto Y, Yamamoto R, Koizumi A, Nara T, Kanda S, Saito M, Narita S, Inoue T, Shimoda N, Tsuchiya N, Ohyama C, Habuchi T. Numakura K, et al. Among authors: muto y. Int J Clin Oncol. 2020 Aug;25(8):1543-1550. doi: 10.1007/s10147-020-01693-y. Epub 2020 May 11. Int J Clin Oncol. 2020. PMID: 32394047
Comparison of pembrolizumab with conventional chemotherapy after first-line platinum-based chemotherapy for advanced urothelial carcinoma in real-world practice: A multicenter retrospective study.
Narita T, Hatakeyama S, Numakura K, Kobayashi M, Muto Y, Saito M, Narita S, Tanaka T, Noro D, Tokui N, Yoneyama T, Hashimoto Y, Habuchi T, Ohyama C. Narita T, et al. Among authors: muto y. Int J Urol. 2021 Sep;28(9):899-905. doi: 10.1111/iju.14601. Epub 2021 May 24. Int J Urol. 2021. PMID: 34028105
Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism.
Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, Kashima S, Yamamoto R, Koizumi A, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Kobayashi M, et al. Among authors: muto y. Genes (Basel). 2022 Jul 5;13(7):1204. doi: 10.3390/genes13071204. Genes (Basel). 2022. PMID: 35885987 Free PMC article.
Real clinical outcomes of nivolumab plus ipilimumab for renal cell carcinoma in patients over 75 years old.
Kobayashi M, Numakura K, Hatakeyama S, Ishida T, Koizumi A, Tadachi K, Igarashi R, Takayama K, Muto Y, Sekine Y, Sobu R, Sasagawa H, Akashi H, Kashima S, Yamamoto R, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Kobayashi M, et al. Among authors: muto y. Int J Clin Oncol. 2023 Nov;28(11):1530-1537. doi: 10.1007/s10147-023-02394-y. Epub 2023 Aug 8. Int J Clin Oncol. 2023. PMID: 37552353
1,008 results